On October 23, 2025, NLS Pharmaceutics Ltd. and Kadimastem Ltd. announced that they had received Nasdaq approval for the proposed merger. The approval is a key regulatory milestone that allows the combined entity to be listed on the Nasdaq exchange, removing a major hurdle in the transaction process.
The companies confirmed that the merger, which will create a new entity named NewcelX, is expected to close on October 30, 2025. With Nasdaq approval in hand, integration activities can commence immediately, accelerating the timeline toward a completed transaction.
The merger combines NLS’s CNS pipeline with Kadimastem’s cell‑therapy platform for neurodegenerative diseases and diabetes, broadening the combined company’s therapeutic scope and market opportunity. This development represents a significant step forward for both companies and provides investors with a clearer path to value creation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.